{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T16:46:49Z","timestamp":1782751609060,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":2259,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.exphem.2015.05.019","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T06:06:43Z","timestamp":1452665203000},"page":"223-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ex\u00a0vivo evaluation of the effect of regulatory T cells on the anti-tumor activity\u00a0of bortezomib in multiple myeloma"],"prefix":"10.1016","volume":"44","author":[{"given":"Ayse Pinar","family":"Ercetin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Ozcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safiye","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faize","family":"Yuksel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serife Medeni","family":"Solmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokmen Omur","family":"Sevindik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Katgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozden","family":"Piskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Undar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2015.05.019_bib1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1182\/asheducation-2003.1.248","article-title":"Advances in biology and therapy of multiple myeloma","author":"Barille-Nion","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2015.05.019_bib2","first-page":"49","article-title":"Multiple myeloma: Clusters, clues and dixoins","volume":"6","author":"Schwartz","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.exphem.2015.05.019_bib3","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.exphem.2015.05.019_bib4","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.ejca.2005.11.035","article-title":"Myeloma bone disease and treatment options","volume":"42","author":"Yeh","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.exphem.2015.05.019_bib5","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ejca.2005.12.026","article-title":"Signalling and survival pathways in multiple myeloma","volume":"42","author":"Bommert","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.exphem.2015.05.019_bib6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.05.019_bib7","first-page":"93","article-title":"Current trends in the diagnosis, therapy and monitoring of the monoclonal gammopathies","volume":"30","author":"Mollee","year":"2009","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.exphem.2015.05.019_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple myeloma","author":"Anderson","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.exphem.2015.05.019_bib9","first-page":"183","article-title":"Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs","volume":"10","author":"Ciolli","year":"2013","journal-title":"Clin Cases Miner Bone Metab"},{"key":"10.1016\/j.exphem.2015.05.019_bib10","doi-asserted-by":"crossref","first-page":"6270","DOI":"10.1158\/1078-0432.CCR-06-0845","article-title":"New potential targets for treating myeloma bone disease","volume":"12","author":"Roodman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2015.05.019_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.drup.2005.06.001","article-title":"Perspectives for combination therapy to overcome drug resistant multiple myeloma","volume":"8","author":"Catley","year":"2005","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.exphem.2015.05.019_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.critrevonc.2014.05.003","article-title":"Linking the activity of bortezomib in multiple myeloma and autoimmune diseases","volume":"92","author":"Skrott","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.exphem.2015.05.019_bib13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.4049\/jimmunol.0902856","article-title":"Cutting edge: Bortezomib treated tumors sensitized to NK cell apoptosis paradoxically acquire resistance to antigen-specific T cells","volume":"184","author":"Lundqvist","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2015.05.019_bib14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5606\/tji.2013.267","article-title":"Measurement methods of cell proliferation and a comparison of various commercial proliferation kits","volume":"1","author":"Terzioglu","year":"2013","journal-title":"Turk J Immunol"},{"key":"10.1016\/j.exphem.2015.05.019_bib15","unstructured":"Biology Stack Exchange. What is an \u2018ex\u00a0vivo\u2019 experiment?. Available at: http:\/\/biology.stackexchange.com\/questions\/10664\/what-is-an-ex-vivo-experiment"},{"key":"10.1016\/j.exphem.2015.05.019_bib16","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.3109\/10428194.2013.825905","article-title":"Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state","volume":"55","author":"Favaloro","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"10.1016\/j.exphem.2015.05.019_bib17","doi-asserted-by":"crossref","first-page":"e49446","DOI":"10.1371\/journal.pone.0049446","article-title":"Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: A cause for immune impairment","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2015.05.019_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2015.05.019_bib19","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/TP.0b013e3181bd7b3a","article-title":"Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates","volume":"88","author":"Kim","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.exphem.2015.05.019_bib20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3324\/haematol.2008.005017","article-title":"Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population","volume":"94","author":"Blanco","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2015.05.019_bib21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.leukres.2010.11.010","article-title":"Significantly reduced regulatory T cell population in patients with untreated multiple myeloma","volume":"35","author":"Gupta","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2015.05.019_bib22","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2015.05.019_bib23","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbrc.2013.07.044","article-title":"Natural CD8+25+ regulatory T cell-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma","volume":"438","author":"Xie","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.exphem.2015.05.019_bib24","doi-asserted-by":"crossref","first-page":"e95765","DOI":"10.1371\/journal.pone.0095765","article-title":"Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma","volume":"9","author":"Hu","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.exphem.2015.05.019_bib25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00431-013-1937-3","article-title":"Lack of CD4+CD25+FOXP3+ regulatory T cells is associated with resistance to intravenous immunoglobulin therapy in patients with Kawasaki disease","volume":"172","author":"Hirabayashi","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.exphem.2015.05.019_bib26","first-page":"931291","article-title":"The role of foxp3-expressing regulatory T cells and T helpers in immunopathogenesis of multidrug resistant pulmonary tuberculosis","volume":"2012","author":"Churina","year":"2012","journal-title":"Tuberc Res Treat"},{"key":"10.1016\/j.exphem.2015.05.019_bib27","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.bbmt.2013.05.011","article-title":"Effects of bortezomib on the immune system: a focus on immune regulation","volume":"19","author":"Mohty","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.exphem.2015.05.019_bib28","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.4049\/jimmunol.1103826","article-title":"Immune mechanism of the antitumor effects generated by bortezomib","volume":"189","author":"Chang","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2015.05.019_bib29","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40259-013-0050-5","article-title":"Treatment of graft-versus-host disease with naturally occurring T regulatory cells","volume":"27","author":"Trzonkowski","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.exphem.2015.05.019_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1479-5876-11-135","article-title":"Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients","volume":"11","author":"Ridolfi","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2015.05.019_bib31","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/pcmr.12055","article-title":"Circulating CD4+ CD25(high) CD127(low) regulatory T cells are an independent predictor of advanced melanoma","volume":"26","author":"Gambichler","year":"2013","journal-title":"Pigment Cell Melanoma Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16000035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X16000035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:32:29Z","timestamp":1759566749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X16000035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0301472X16000035"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2015.05.019","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex\u00a0vivo evaluation of the effect of regulatory T cells on the anti-tumor activity\u00a0of bortezomib in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2015.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}